[go: up one dir, main page]

PE20091378A1 - Polipeptidos agonistas plexind1 - Google Patents

Polipeptidos agonistas plexind1

Info

Publication number
PE20091378A1
PE20091378A1 PE2009000023A PE2009000023A PE20091378A1 PE 20091378 A1 PE20091378 A1 PE 20091378A1 PE 2009000023 A PE2009000023 A PE 2009000023A PE 2009000023 A PE2009000023 A PE 2009000023A PE 20091378 A1 PE20091378 A1 PE 20091378A1
Authority
PE
Peru
Prior art keywords
plexind1
seq
agonist polypeptides
polypeptides
semaforin
Prior art date
Application number
PE2009000023A
Other languages
English (en)
Inventor
Ryan J Watts
Alexander W Koch
Vigne Marc Tessier-La
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20091378A1 publication Critical patent/PE20091378A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

REFERIDA A UN POLIPEPTIDO QUE COMPRENDE UN FRAGMENTO DE SEMAFORINA SEMA3E QUIMERICO QUE CARECE DEL PRIMER SITIO DE ESCISION DE FURINA Y QUE COMPRENDE UN LIGANTE TAL COMO GRAG (SEC ID NO:2) Y GGGS (SEC ID NO:3). TAMBIEN ESTA REFERIDA A UN ACIDO NUCLEICO, UN VECTOR Y UNA CELULA HUESPED. DICHOS POLIPEPTIDOS SON AGONISTAS DE PLEXIND1 Y SON UTILES EN EL TRATAMIENTO DE ANGIOGENESIS ASOCIADA AL CANCER
PE2009000023A 2008-01-10 2009-01-09 Polipeptidos agonistas plexind1 PE20091378A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2029608P 2008-01-10 2008-01-10

Publications (1)

Publication Number Publication Date
PE20091378A1 true PE20091378A1 (es) 2009-10-14

Family

ID=40481787

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000023A PE20091378A1 (es) 2008-01-10 2009-01-09 Polipeptidos agonistas plexind1

Country Status (5)

Country Link
US (1) US20090181035A1 (es)
AR (1) AR070134A1 (es)
PE (1) PE20091378A1 (es)
TW (1) TW200934512A (es)
WO (1) WO2009089461A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9808506B2 (en) 2007-10-19 2017-11-07 Rappaport Family Institute For Research In The Medical Sciences Compositions comprising semaphorins for the treatment of cancer and methods of selection thereof
WO2009050691A2 (en) 2007-10-19 2009-04-23 Rappaport Family Institute For Research In The Medical Sciences Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof
GB2493992A (en) 2011-08-26 2013-02-27 Fillaball Holdings Ltd Wheeled load-carrying apparatus
AU2010245668B2 (en) 2009-05-08 2016-07-14 Vaccinex, Inc. Anti-CD100 antibodies and methods for using the same
EP2385121A1 (en) * 2010-05-06 2011-11-09 Netris Pharma Antagonists of Sema3E/PlexinD1 interaction as anti-cancer agents
IT1400024B1 (it) * 2010-05-21 2013-05-17 Uni Politecnica Delle Marche Uso farmaceutico di semaforine.
US20130095118A1 (en) 2011-10-11 2013-04-18 Vaccinex, Inc. Use of Semaphorin-4D Binding Molecules for Modulation of Blood Brain Barrier Permeability
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
WO2014181273A1 (en) * 2013-05-08 2014-11-13 University Of Manitoba Methods for treating inflammatory bowel disease
JP6611709B2 (ja) * 2013-06-25 2019-11-27 バクシネックス インコーポレーティッド 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン−４ｄ阻害分子の使用
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
WO2017000059A1 (en) * 2015-06-29 2017-01-05 The University Of British Columbia B1sp fusion protein therapeutics, methods, and uses
KR102353086B1 (ko) * 2018-09-07 2022-01-20 아주대학교산학협력단 신규 면역독소 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006898A2 (en) * 2002-07-11 2004-01-22 Sema Aps Use of compounds capable of inhibiting the proteolytic processing of semaphorins for prevention, treatment, diagnosis and prognosis of an invasive disease
BRPI0613425A2 (pt) * 2005-07-21 2012-10-30 Stichting Katholieke Univ plexina d1, uso de moléculas, moléculas de ligação de plexina d1, composição diagnóstica, composição terapêutica, e, método para identificar moléculas que são capazes de se ligar a plexina dl

Also Published As

Publication number Publication date
TW200934512A (en) 2009-08-16
WO2009089461A1 (en) 2009-07-16
US20090181035A1 (en) 2009-07-16
AR070134A1 (es) 2010-03-17

Similar Documents

Publication Publication Date Title
PE20091378A1 (es) Polipeptidos agonistas plexind1
ES2545895T3 (es) Proteína de fusión anticancerígena
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
MY202029A (en) T-cell modulatory multimeric polypeptides and methods of use thereof
AR068553A1 (es) Vacunas y componentes de vacuna para la inhibicion de celulas microbianas
CL2012003077A1 (es) Polipeptido que comprende el decimo dominio de fibronectina tipo iii (10fn3), en donde el dominio 10fn3 se une al dominio 1 o 2 de seroalbumina humana, y donde la vida media del suero del polipéptido en presencia de seroalbumina es al menos 5 veces mayor que en su ausencia; acido nucleico que lo codifica; vector que lo comprende; celula hospedera que lo expresa; composición que lo comprende; y su uso para tratar la diabetes.
PH12014501602A1 (en) Chimeric factor viii polypeptides and uses thereof
CL2014001317A1 (es) Polipeptido aislado que tiene actividad de lisozima; polinucleotido aislado que lo codifica; construccion de acido nucleico o vector de expresion; celula huesped recombinante; metodo de produccion; composicion que lo comprende, ya sea detergente o de alimentacion animal o aditivo de alimentacion animal; y su uso.
EA201591515A1 (ru) Полипептиды il-22, химерные белки il-22 fc и их применение
EA038402B9 (ru) Аденовирусные полинуклеотиды и полипептиды
MX2014005728A (es) Anticuerpos especificos para antigeno de la superficie celular de trofoblasto-2 y sus usos.
CL2013000475A1 (es) Polipeptidos de relaxina que comprende uno o mas aminoacidos codificados no naturales; acido nucleico aislado; metodo para preparar el polipeptido de relaxina.
BR112015020111A8 (pt) célula de levedura recombinante, vetores para a expressão funcional de um polipeptídeo heterólogo, método para preparar um álcool, ácido orgânico ou aminoácido, uso de dióxido de carbono, e, microorganismo recombinante
MX383142B (es) Composiciones que comprenden polipéptidos que tienen actividad xilanasa y polipéptidos que tienen actividad arabinofuranosidasa.
EA200971142A1 (ru) Система экспрессии гетерологичных и гомологичных целлюлаз
BR112012014104A2 (pt) método de geração de células destrutoras naturais e células dendríticas de hemangioblastos embrionários humanos derivados de células-tronco
EP4219702A3 (en) Enzyme variants and polynucleotides encoding the same
AR081242A1 (es) Receptores pyr/pyl modificados activados por ligandos ortogonales
CL2009000862A1 (es) Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer.
CL2008002233A1 (es) Anticuerpo o un fragmento del mismo que reconoce especificamente el receptor ephb4; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar cancer.
PE20120400A1 (es) Contrucciones de casb7439
EA201691548A1 (ru) Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды
PH12020552291A1 (en) System and methods for engineering bacteria fit for eukaryotic mrna production, export, and translation in a eukaryotic host
IN2013MU02527A (es)
EA033091B1 (ru) ПШЕНИЦА С НОВЫМИ АЛЛЕЛЯМИ Rht-B1

Legal Events

Date Code Title Description
FD Application declared void or lapsed